Effect of topical gentamicin in preventing surgical site infection in elective incisional hernia repair: a randomized controlled trial

Effect of topical gentamicin in preventing surgical site infection in elective incisional hernia repair: a randomized controlled trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Effect of topical gentamicin in preventing surgical site infection in elective incisional hernia repair: a randomized controlled trial Nils Jimmy Hidalgo, Montserrat Juvany, Salvador Guillaumes, Carlos Hoyuela, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4703140/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 20 Nov, 2024 Read the published version in Scientific Reports → Version 1 posted 10 You are reading this latest preprint version Abstract Surgical site infection (SSI) continues to be a common complication of surgery. The real benefit of using topical antibiotics for the prevention of SSI in abdominal hernia repair surgery is still unknown. This study aimed to evaluate the usefulness of topical gentamicin in SSI prophylaxis in incisional hernia repair with mesh. A randomized controlled trial was conducted in patients undergoing open incisional hernia repair. Patients were randomly assigned to one of two groups: in the gentamicin group, each layer of the abdominal wall was irrigated with gentamicin solution before wound closure, and in the saline solution group (placebo), each layer of the abdominal wall was irrigated with normal saline solution. The incidence of SSI and other surgical site complications was compared between both groups, and the presence of adverse effects with the use of topical gentamicin. Data from 146 patients were included for analysis: 74 in the gentamicin group and 72 in the saline solution group. SSI was observed in six patients (8.1%) in the gentamicin group and eight patients (11.1%) in the saline solution group, with no significant differences (p = 0.538) between both groups. No statistically significant differences were observed in the presentation of seroma, hematoma, and surgical wound dehiscence between both groups. No adverse effects were reported from topical application of gentamicin. In this clinical trial, the use of topical gentamicin in incisional hernia repair with mesh did not significantly reduce the incidence of SSI. EU Clinical Trials Register: EudraCT 2018-001860-45 (04/07/2019). Health sciences/Diseases Health sciences/Medical research surgical site infection topical antibiotics gentamicin prevention incisional hernia repair Figures Figure 1 INTRODUCTION Surgical site infection (SSI) continues to be one of the most common complications of surgery despite advances in surgical technology and prevention measures, accounting for up to 20% of all healthcare-associated infections 1 . SSI is the second leading cause of hospital-acquired infection and remains one of the most common preventable infections today 2,3 . The estimated incidence of SSI is around 5% 4–6 . However, this may be an underestimated rate, given that approximately 50% of SSIs is diagnosed outside the hospital after the patient has been discharged 1,7 . Additionally, the incidence of SSI varies greatly depending on several factors, such as the type of surgical procedure performed. In colorectal surgery, the incidence of SSI can be up to 32% 8 . After abdominal wall surgery, inguinal hernia infection rates range from 2.4–4.9% 9,10 , while those of incisional hernia can reach 33% 11 . SSI causes increased morbidity and mortality 7,12 , impairs the wound healing process, resulting in a higher probability of having an incisional hernia 13 , prolongs hospital stay 14 , and causes higher healthcare costs 15 . The incidence of infectious complications is one of the most important outcome measures in surgery, so everything possible must be done to design effective methods to reduce them. Among measures to prevent SSI, topical antibiotics have been used for decades in surgical practice 16,17 however, there is still controversy about their use, and there is a lack of consistent evidence on the effectiveness of this measure. The World Health Organization (WHO) guidelines do not recommend topical antibiotics before wound closure 18 . The Centers for Disease Control and Prevention (CDC) guidelines also advise against applying ointments, solutions, or powders to the incision site but indicate that irrigation with antibiotic agents of intra-abdominal, deep tissues, or subcutaneous remains an unresolved question 2 . Evidence evaluated by some meta-analyses also demonstrated that topical antibiotics before wound closure could not be recommended 19,20 . On the other hand, two recent meta-analyses concluded that the use of topical antibiotics probably prevents SSI compared to placebo and antiseptics, but that these results should be taken with caution due to the low number of studies used for comparison and the low statistical power from some studies 21,22 Overall, high-quality data supporting the use of topical antibiotics for SSI prevention is lacking; however, there may be benefits in specific procedures and populations such as joint arthroplasty, cataract surgery, spine surgery, and obese patients undergoing abdominal surgery and, specifically, colorectal resections 2,23 . In summary, the use of topical antibiotics cannot currently be recommended, but clinical trials evaluating their effectiveness are still necessary 19 . SSI represents a major concern in mesh ventral hernia repair because of the risk of a devastating complication such as mesh infection that can occur in up to 7%-10% of patients 24 . Additionally, SSI is associated with increased morbidity, poorer quality of life, increased costs, and hernia recurrence 25–28 . Clinical studies analyzing topical antibiotics in abdominal wall surgery are scarce, carried out mainly in inguinal hernia repair 29,30 , and experimental studies with good results after using prosthetic material with gentamicin 31,32 . Considering this, we believe conducting clinical trials on this topic is necessary. The main objective of the present trial was to evaluate the usefulness of topical gentamicin as a prophylaxis for surgical site infection in incisional hernia repair with mesh. Secondary objectives were to evaluate the incidence of other surgical site occurrences and adverse effects or complications associated with the use of topical gentamicin. MATERIALS AND METHODS Study design A randomized controlled trial was conducted in patients undergoing open incisional hernia repair from March 2017 to March 2021. The study was carried out at the Hospital Plató, a basic general hospital with a high workload in abdominal wall surgery. Since 2021, it has been part of the Hospital Clínic Barcelona, a tertiary reference center. The trial was registered in the European database of clinical trials with medicines EudraCT ( www.clinicaltrialsregister.eu ) with the identifier 2018-001860-45 (04/07/2019). The manuscript was prepared following the guidelines of the CONSORT (Consolidated Standards of Reporting Trials) statement 33 . Eligibility criteria The inclusion criteria were adults 18 years or older and elective open ventral incisional hernia repair surgery. The incisional hernia was diagnosed by clinical examination or imaging findings with ultrasound or abdominal tomography. The exclusion criteria were known allergic reaction to aminoglycosides, parastomal hernia, repair by minimally invasive surgery, performance of another concomitant surgical procedure, infection at the time of surgery, antibiotic treatment until less than 48 hours before surgery, and patients who did not wish to participate in the study. Preoperative and intraoperative data collection For each patient, demographic data (age, sex, body mass index), comorbidities (diabetes mellitus, heart disease, chronic lung disease, kidney disease, liver disease, obesity), use of immunosuppressive medication or steroids, tobacco consumption, anesthetic risk using the American Society of Anesthesiologists (ASA) classification 34 , and presence of recurrent incisional hernia. The intraoperative data recorded were operative time, hernia size, hernia size classification according to the European Hernia Society (EHS) 35 , location of the hernia according to the EHS classification 35 , size of the mesh used, abdominal wall plane where the mesh was placed, associated intestinal resection, and drain placement. Random sequence generation and blinding Randomization was done after the preoperative visit, and the patient's consent was obtained to participate in the trial. Randomization was performed with the Spanish version of the free and open-source OxMaR system software available online 36 . Restricted randomization was performed through minimization to assign patients to groups. Criteria for minimization were sex (male, female), age, diabetes mellitus, and body mass index (BMI). Patients were randomly assigned to one of two groups: gentamicin group and saline solution (placebo) group. The study was double-blind, where the patients did not know the group to which they were assigned, and the outcome assessors were also unaware of the treatment groups. The operating surgeons and operating room nurses were aware of the nature of the study and the assignment of patients to each group at the time of surgery. Surgical procedure Procedures were performed under general or spinal anesthesia with patients lying supine. A dose of 2 g of intravenous cefazolin was administered 30 minutes before surgery, and 600 mg of intravenous clindamycin was administered to patients with beta-lactam allergy. All procedures were performed using an open approach by two surgeons with experience in abdominal wall surgery. Before starting surgery, the skin was prepared by washing with chlorhexidine soap and painting the surgical field with 2% alcoholic chlorhexidine. A spindle incision of the skin was made with the excision of the scar from the previous surgery, the subcutaneous cellular tissue opening, identification, and dissection of the hernial sac. To repair the hernia defect, a 60 g/m2 monofilament polypropylene mesh with a 1.15 mm pore was used, placed according to the characteristics of the hernia at the preperitoneal, retromuscular or supra aponeurotic level. The meshes were fixed with a poly-4-hydroxybutyrate monofilament absorbable synthetic suture. The aponeurosis closure was performed with a continuous suture according to the small bite technique using absorbable monofilament synthetic suture of poly-4-hydroxybutyrate, the closure of the subcutaneous cellular tissue with absorbable multifilament synthetic suture of polyglactin 910 and the skin with a continuous intradermal suture with absorbable monofilament synthetic of polyester Glycomer 631. Depending on the characteristics of the hernia and the surgeon's choice, a closed system drain was placed in the retromuscular or subcutaneous space, inserted through an incision in the skin far from the surgical wound. Study intervention After placing the mesh in the gentamicin group, each layer of the abdominal wall was irrigated with 160 mg of gentamicin diluted in 500 ml of normal saline solution (0.9% NaCl). In the saline solution (placebo) group, each layer of the abdominal wall was irrigated with 500 ml of normal saline solution. After the intervention, the surgical wound was closed. Postoperative care In the hospitalization room, vital signs and drainage (if present) were evaluated. Analgesia during admission was achieved with paracetamol 1g every eight hours and dexketoprofen every eight hours intravenously. Systemic or topical antibiotics were not routinely administered postoperatively. The wounds were examined every day by a surgeon until discharge. Drains were removed before discharge if the discharge was scant and had non-haematic characteristics. The surgical wound dressings were removed on the second postoperative day, and showering was permitted. Oral analgesia at discharge was with paracetamol and dexketoprofen. Follow-up Patient follow-up was carried out in outpatient surgery consultations at seven days, 30 days, six months, and 12 months after the intervention. The surgical outcome was evaluated by a surgeon who was not involved in the surgery and was unaware of the group assignment. At each visit, wound healing was assessed, and complications, including SSI, were recorded. If SSI with discharge was detected, wound cultures were taken. Primary outcome The study's primary outcome was the incidence of SSI (superficial, deep, and organ/space), which was defined according to the criteria developed by the CDC 7 . These criteria define superficial SSI as occurring up to 30 days after surgery and affecting only the skin or subcutaneous tissue. Deep SSI was defined as one that involves deep soft tissues such as fascia and muscle that occur up to one year after surgery if a prosthesis is placed. Organ/space infection was defined as infection deeper than the fascia or muscular wall, which has been opened or manipulated during the surgical procedure. Secondary outcomes The incidence of other surgical site occurrences such as seroma (bag of sterile, clear serous fluid at the incision site), hematoma (accumulation of blood or clots in the surgical wound), wound dehiscence, or enterocutaneous fistula was analyzed 26 . The isolation of microorganisms in surgical wound samples in patients with SSI and the treatment performed in patients with SSI, such as systemic antibiotics, drainage of abscesses, or need for reintervention to remove the mesh, were analyzed. Other outcomes analyzed were postoperative complications outside the surgical site, postoperative complications according to the Clavien-Dindo classification 37 , hospital stay, mortality 30 days after surgery, and hernia recurrence after one year of follow-up. Adverse events that were potentially attributable to the study antibiotic were also reported. An independent data and safety monitoring committee monitored the trial continuously. Sample size calculation The primary endpoint for calculating the required sample size was the incidence of surgical wound infection. Based on the results of two clinical trials 38,39 , we assumed an SSI rate of 23% in the group without topical gentamicin and 6% in the group with topical gentamicin. The sample size calculated was 146 patients to identify this difference with an alpha error of 0.05 and a power of 0.8. The dropout rate was expected to be 5%; therefore, we aimed for a total sample size of 154 patients. Due to the low dropout rate, we ended recruitment after 150 patients. The sample size was calculated with Gpower 3.1 software. Statistic analysis Categorical variables were analyzed using Pearson's Chi-square or Fisher's exact tests. For continuous variables, the normality of the data distribution was tested using the Kolmogorov-Smirnov test. The student t-test was used to analyze differences in continuous variables with a normal distribution, and the non-parametric Mann-Whitney U test was used to analyze continuous variables with a non-normal distribution. A level of p < 0.05 was considered to establish statistical significance. A per-protocol approach was used for data analysis. Statistical analyses were performed using IBM SPSS 27.0 software (Armonk, NY: IBM Corp). Ethics The protocol of this trial was approved by the drug research ethics committee of the Catalan Union of Hospitals Foundation, and its implementation was authorized by the Spanish Agency for Medicines and Health Products. All eligible patients gave written informed consent. This study was performed in accordance with the Declaration of Helsinki. RESULTS Recruited patients From March 2017 to March 2021, 171 patients admitted for elective incisional hernia repair met inclusion criteria. Nineteen patients were excluded from the study due to refusal to participate, and two patients were due to a history of allergy to aminoglycosides. Finally, 150 patients were randomized; 75 were assigned to the gentamicin group and 75 to the saline solution group. One patient in the gentamicin group and three in the saline solution group were lost to follow-up. Finally, data from 146 patients were included for analysis: 74 in the gentamicin group and 72 in the saline solution group. Figure 1 shows the recruitment flow chart according to CONSORT recommendations 33 . Baseline characteristics of the study groups The mean age was 67.2 ± 11.3 in the gentamicin group and 65.36 ± 14.08 in the saline solution group, with no significant differences between both groups (p = 0.384). The two groups had no significant differences regarding sex, BMI, comorbidities analyzed, anesthetic risk (ASA), and recurrent hernia (Table 1 ). Table 1 Baseline characteristics of study groups Topical gentamicin (N = 74) Topical saline solution (N = 72) p-value Age, Mean ± SD 67.2 ± 11.31 65.36 ± 14.08 0.384 Sex, N (%) 0.517 Male 31 (41.9) 34 (47.2) Female 43 (58.1) 38 (52.8) BMI (Kg/m 2 ), Mean ± SD 30.29 ± 5.74 30.12 ± 5.04 0.84 Comorbidities, N (%) Diabetes mellitus 13 (17.6) 10 (13.9) 0.542 Heart disease 13 (17.6) 10 (13.9) 0.542 Chronic pulmonary disease 9 (12.2) 8 (11.1) 0.843 Renal disease 0 3 (4.2) 0.117 Liver disease 2 (2.7) 0 0.497 Obesity 37 ( 50 ) 38 (52.8) 0.037 Tobacco use 9 (12.2) 8 (11.1) 0.843 Steroid or immunosuppressant use 2 (2.7) 3 (4.2) 0.679 ASA, N (%) 0.377 ASA I 4 (5.4) 6 (8.3) 0.53 ASA II 57 (77) 48 (66.7) 0.164 ASA III 13 (17.6) 18 ( 25 ) 0.272 Recurrent hernia, N (%) 16 (21.6) 18 ( 25 ) 0.629 SD: standard deviation, BMI: body mass index, ASA: American Society of Anesthesiologists classification. Characteristics of the hernia and surgery The mean operating time was 71.84 ± 36.19 min in the gentamicin group and 77.22 ± 41.52 min in the saline solution group, with no significant differences between both groups (p = 0.402). When analyzing the size of the hernia, location of the hernia, mesh size, plane of mesh placement, need for intestinal resection, and use of drainage between both groups, no statistically significant differences were observed (Table 2 ). Table 2 Intraoperative data of study groups Topical gentamicin (N = 74) Topical saline solution (N = 72) p-value Operative time (min), Mean ± SD 71.84 ± 36.19 77.22 ± 41.52 0.402 Hernia size (cm), Mean ± SD Hernia length 6.95 ± 5.28 7.18 ± 5.48 0.964 Hernia width 4.89 ± 2.92 5.13 ± 2.96 0.496 Hernia size classification (EHS), N (%) 0.839 EHS W1 26 (35.1) 22 (30.6) EHS W2 44 (59.5) 46 (63.9) EHS W3 4 (5.6) 4 (5.4) Hernia localization, N (%) 0.078 Medial 64 (86.5) 54 ( 75 ) Lateral 10 (13.5) 18 ( 25 ) Mesh size (cm 2 ), Mean ± SD 220.93 ± 344.51 254.56 ± 279.76 0.129 Mesh placement, N (%) 0.578 Onlay 27 (36.5) 26 (36.1) Retromuscular 39 (52.7) 41 (56.9) Preperitoneal 1 (1.4) 2 (2.8) Onlay + Retromuscular 7 (9.5) 3 (4.2) Intestinal resection, N (%) 1 (1.4) 1 (1.4) 1 Drain use, N (%) 50 (67.6) 47 (65.3) 0.77 SD: standard deviation, EHS: European Hernia Society Outcomes of both groups The incidence of SSI in the entire sample analyzed was 9.6%. SSI was observed in six patients (8.1%) in the gentamicin group and eight patients (11.1%) in the saline solution group, with no significant differences (p = 0.538) between both groups. Six patients in the gentamicin group had superficial infections, seven in the saline solution group had superficial infections, and one had a deep infection (Table 3 ). No organ/space infection was reported in any of the groups. Table 3 Outcomes of study groups Topical gentamicin (N = 74) Topical Saline solution (N = 72) p-value Surgical site occurrence, N (%) Any surgical site occurrence 18 (24.3) 21 (29.2) 0.509 Seroma 8 (10.8) 13 (18.1) 0.212 Hematomas 4 (5.4) 2 (2.8) 0.681 Wound dehiscence 2 (2.7) 5 (6.9) 0.272 Surgical site infection 6 (8.1) 8 (11.1) 0.538 Superficial surgical site infection 6 (8.1) 7 (9.7) 0.732 Deep surgical site infection 0 1 (1.4) 0.493 Mesh infection 0 1 (1.4) 0.493 Cultures performed 3 (4.1) 7 (9.7) 0.206 Positive culture 2 (2.7) 7 (9.7) 0.095 Surgical site infection treatment, N (%) Antibiotic 3 (4.1) 4 (5.6) 0.717 Antibiotic and abscess drainage 3 (4.2) 3 (4.1) 1 Antibiotic, abscess drainage, and remove mesh 0 1 (1.4) 0.493 Other complications, N (%) 4 (5.4) 3 (4.2) 1 Clavien Dindo, N (%) 0.564 I 0 1 (1.4) II 4 (5.4) 3 (4.2) Length of stay (days), Mean ± SD 2.32 ± 2.73 2.86 ± 4.15 0.465 Mortality 30 days, N (%) 0 0 Hernia recurrence, N (%) 2 (2.7) 6 (8.3) 0.163 SD: standard deviation No statistically significant differences were observed in the presentation of seroma, hematoma, and surgical wound dehiscence between both groups. Some complication of the surgical wound (surgical site infection, seroma, hematoma, or wound dehiscence) was observed in 18 patients (24.3%) in the gentamicin group and 21 patients (29.2%) in the saline solution group, without significant differences (p = 0.509). Furthermore, no adverse effects or allergic reactions were reported. Other complications not related to the surgical wound occurred in seven patients: two patients with acute urinary retention, one patient with cardiac arrhythmias, one patient with bronchospasm, one patient with pneumonia, one patient with confusional syndrome, and one patient with paralytic ileus. No significant differences were observed between both groups. No significant differences were also observed between both groups when comparing postoperative complications according to the Clavien-Dindo classification, hospital stay, 30-day mortality, and hernia recurrence at one year of follow-up. No adverse events potentially attributable to the use of the topical antibiotic were reported in patients in the gentamicin group. Details of infected patients All surgical site infections were diagnosed after hospital discharge. In the gentamicin group, three patients were treated with oral antibiotics alone, and three patients required abscess drainage in addition to the antibiotic. In the saline solution group, four patients were treated with oral antibiotics only, three patients with oral antibiotics and abscess drainage, and one patient also required mesh removal (Table 3 ). Surgical wound cultures were performed in 10 patients, and pathogenic microorganisms were isolated in 2 patients in the gentamicin group and seven in the saline solution group. Bacteria resistant to gentamicin were Enterococcus faecalis (in 1 of 2 isolates) and Pseudomonas aeruginosa (in 1 of 2 isolates). Gentamicin-resistant bacteria were isolated in two patients in the gentamicin group. The bacteria isolated in the samples and the antibiotic resistance in both groups are detailed in Table 4 . Table 4 Type of bacteria isolated in cultures from the infected surgical site. Case Allocated intervention Bacteria isolated (R: resistant antibiotic) 1 Topical gentamicin Enterococcus faecalis (R: Erythromycin, Tetracycline, Cotrimoxazole, Fosfomycin, Gentamicin) Peptoniphilus harei (R: Erythromycin, Clindamycin, Tetracycline) Actinomyces turicensis (R: Metronidazole) 2 Topical gentamicin Pseudomonas aeruginosa (R: Gentamicin) Citrobacter freundii (R: Ampicillin, Amoxicillin/clavulanic, Cephalothin) 3 Topical gentamicin Negative 4 Topical saline solution Enterococcus faecalis (R: Erythromycin, Tetracycline, Cotrimoxazole, Fosfomycin) Citrobacter koseri (R: Ampicillin) 5 Topical saline solution Staphylococcus aureus (R: Penicillin) Pseudomonas aeruginosa (R: Ampicillin/sulbactam, Cefotaxime, Minocycline, Cotrimoxazole) 6 Topical saline solution Escherichia coli (R: Ampicillin, Piperacillin, Ciprofloxacin, Levofloxacin) 7 Topical saline solution Serratia marcescens (R: Ampicillin, Amoxicillin/clavulanic, Cefuroxime, Tobramycin) Staphylococcus aureus (R: Erythromycin, Clindamycin, Streptococcus agalactiae (R: Tetracycline) 8 Topical saline solution Proteus mirabilis (R: Nalidixic acid, Fosfomycin) Enterococcus faecium (R: Penicillin, Ampicillin, Cefuroxime, Imipenem, Ciprofloxacin, Levofloxacin, Erythromycin, Clindamycin, Cotrimoxazole, Streptomycin, Kanamycin) 9 Topical saline solution Proteus mirabilis (R: Tigecycline) Staphylococcus aureus (R: none) 10 Topical saline solution Staphylococcus aureus (R: Penicillin) DISCUSSION In this randomized controlled trial, topical gentamicin before wound closure of incisional hernia repair with mesh did not significantly reduce the incidence of SSI. There were also no significant differences in the incidence of other local complications or adverse effects due to topical gentamicin. SSI is a common postoperative complication associated with worse outcomes and higher costs 12,15 . In a recent study in the U.S., SSI was the most common infection associated with medical care, representing 42% of these infections 40 . The incidence of SSI varies depending on several factors, such as the type of surgical procedures, the context in which the operations are performed, patient comorbidities, surveillance criteria used, and the quality of data collection. Overall, the incidence of SSI in clean surgical procedures is only 2%. In comparison, reported rates for wall reconstruction procedures range from 2.4–4.9% in inguinal hernias 9,10 , between 4% and 16% in ventral hernias 41–44 and 23–33% in incisional hernias 11,38 . Although the presence of prosthetic mesh does not increase the incidence of infection 45 , SSI after hernia repair with mesh is a difficult complication to solve and is associated with high morbidity, occasionally requiring reintervention for removal of the infected mesh, increases the risk of hernia recurrence and increases healthcare costs 27,41,46 . Implementation of evidence-based protocols can prevent up to 50–60% of all SSIs 2,4,47 . The WHO and the CDC have developed guidelines for preventing SSIs 2,18,48 . Some practices to prevent SSI include adequate preoperative preparation, sterilization of the surgical site with antiseptics, proper surgical technique, and administration of prophylactic antibiotics 4,7 . The incidence of SSI in our study was 9.6% in the entire sample analyzed, lower than in previous years in our center, probably because conducting the clinical trial required stricter follow-up of these guidelines. Among the measures to reduce the incidence of SSI after surgery, topical antibiotics have been proposed. However, the evidence is currently low quality, so its efficacy remains uncertain 20,49 and is generally reserved for at-risk patients (e.g. diabetes, immunosuppression, obesity) or high-risk procedures (e.g clean-contaminated procedures, colorectal surgery, implantation of prosthetic materials) 5,50 . Commonly used antibiotics are beta-lactams, cephalosporins, aminoglycosides, glycopeptides, chloramphenicol, and bacitracin 51–53 with different methods and doses of administration. To carry out this clinical trial, we chose gentamicin because it is effective against gram-negative and gram-positive bacteria such as staphylococci (S. aureus and S. epidermidis) because the local concentration achieved could be sufficient to exert a potential effect against resistant species and because it presents limited systemic toxicity 54 . Furthermore, favorable results have been described with topical gentamicin in experimental studies with mesh 32,55,56 and clinical studies performed in inguinal hernia repair with mesh 29,57 . Our results show a lower proportion of SSIs in the gentamicin group; however, this difference was not statistically significant. Previous clinical trials conducted in inguinal hernia surgery 29 , cardiothoracic surgery 58 and colorectal surgery 23,59 found a significant reduction in SSI. In these studies, unlike our clinical trial, gentamicin implants or sponges were used, which could favor a longer release of the antibiotic. However, other clinical trials have shown that the use of topical gentamicin, even in the form of gentamicin sponge implantation, does not produce a relevant reduction in the rate of SSI 30,60–62 Few studies analyze SSI rates, differentiating them into superficial and deep. A clinical trial carried out in patients undergoing sternotomy compared the results of using a sponge with gentamicin and a sponge with placebo, observing that the rate of superficial infection was similar in both groups; however, the rate of deep infection was reduced in the group with gentamicin 58 . Our study did not find significant differences in superficial or deep infection between the gentamicin and saline solution (placebo) groups. The importance of having information about deep infections in abdominal wall repair surgery is the associated risk of mesh infection. An estimated incidence of mesh infection is between 6% and 10% for incisional hernia repair 24 . In our study, only one patient with mesh infection was identified as belonging to the saline solution group and who required reintervention for mesh removal during study follow-up. The low incidence of mesh infection in our sample could be explained by the selection of patients for randomization, where we excluded parastomal hernias, emergency surgeries, and the presence of active infection. The bacteria most associated with SSI are Staphylococcus aureus (30%), followed by coagulase-negative staphylococcus (13.7%), enterococcus species (11.2%), and Escherichia coli (9.6%) 63 . Most SSIs are caused by microorganisms at the incision site and introduced during surgery. The contaminating germ can come from the patient's flora or a hospital-transmitted germ. The hospital microbial environment, medical conditions, and patient-specific risk factors determine the pathogenic microorganism and the risk of infection 64 . In our sample, the most frequently isolated bacteria were Staphylococcus aureus in four patients, Enterococcus faecalis in two patients, and Pseudomonas aeruginosa in two. Excessive or unnecessary exposure to antibiotics is the cause of increasing resistance to these drugs 65 . A possible adverse effect of topical antibiotics is the risk of increasing resistance; for this reason, the WHO guidelines do not recommend their use 2,18 . However, the real risk of antibiotic resistance after local application has not yet been quantified, and its use must be weighed in situations where the benefit may outweigh the risk, such as in procedures with a high infection rate or devastating infectious complications. In our study, bacteria resistant to gentamicin were isolated in two patients belonging to the gentamicin group, which could be related to its local use. Furthermore, it should be considered that all patients received a prophylactic dose of intravenous cephalosporin, which may influence the microorganisms isolated in the cultures and resistance. The results of comparing topical prophylaxis with systemic prophylaxis and whether there is a synergistic effect when using local and systemic prophylaxis are not yet known with certainty. An argument favoring topical prophylaxis is that it allows a higher antibiotic concentration at the wound level. In contrast, the blood concentration remains low, reducing complications such as ototoxicity and nephrotoxicity associated with gentamicin 66 . However, the greatest disadvantage of topical prophylaxis is that it occurs after making the incision, while the recommendation to reduce SSI is that there should be adequate concentrations of the antibiotic at the surgical site when starting the incision 4,7 . Surgical site occurrences are a quality measure of hospitals and surgeons 67 , which cause considerable morbidity, increase costs, and are associated with an increased risk of hernia recurrence 68 . The effect of topical gentamicin on developing other surgical site occurrences and SSI has also been described in the literature. A clinical trial in which gentamicin lavage of the axillary dissection site was performed after lymph node excision did not observe a significant reduction in the incidence of seroma 69 . Experimental studies have also been conducted on the effect of gentamicin on healing with contradictory results 70,71 . Our results do not show statistically significant differences in the presentation of the surgical wound's seroma, hematoma, or dehiscence. In this clinical trial, no adverse reactions related to the use of topical gentamicin were reported. The adverse reactions described using topical antibiotics vary from contact dermatitis in dermatological surgery to intraoperative anaphylactic shock 72,73 . The incidence of adverse reactions related to topical antibiotics is low 72,74 however, few studies have addressed this issue, and the pharmacokinetics of the administered antibiotics are not well reported, so the exact risk is still unknown. The limitations of this clinical trial include the fact that it was a study conducted in a single hospital, which reduces its external validity. One-year follow-up may not be sufficient to detect rare complications associated with surgical mesh that may occur up to five years after incisional hernia repair 75 . However, since the trial's primary objective is to determine the rate of SSI, the follow-up time of this study is sufficient to meet the criteria defining SSI 7 . Based on data from previous clinical trials, the estimated incidence of SSI for the placebo group was higher than the real incidence detected in this study, which influenced the calculation of the sample size and, therefore, the power. Among the strengths of this study is the inherent characteristic of a clinical trial that allows selection biases to be reduced. Factors associated with the development of SSI such as age, obesity, diabetes mellitus, chronic obstructive pulmonary disease, use of steroids, immunosuppressants, smoking, prolonged operative time, location of mesh placement, mesh size, and associated intestinal resection 42–44 , were distributed evenly in both groups analyzed. Furthermore, this study is one of the first clinical trials to analyze the use of topical gentamicin to prevent SSI in incisional hernia surgery. CONCLUSIONS In this clinical trial, the use of topical gentamicin in incisional hernia repair with mesh did not significantly reduce the incidence of SSI. Topical gentamicin did not significantly change the proportion of other surgical site complications. It is still necessary to carry out more studies that analyze the benefits of using topical antibiotics in preventing SSI, the risk of resistance, the pharmacokinetics of their topical application, and possible adverse effects. Declarations Data availability The trial protocol and datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Author contributions: NJ.H: project development, data collection and analysis, manuscript writing and editing. M.J: project development, data collection and analysis, manuscript editing. S.G: project development, data analysis, manuscript writing and editing. C.H: data collection, manuscript editing. O.V: data analysis, manuscript editing. M.P: data analysis, manuscript writing and editing. All authors reviewed and approved the manuscript. Competing Interests: The authors declare no competing interests. Additional information Correspondence and requests for materials should be addressed to NJ.H. References Magill, S. S. et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370, 1198–208 (2014). Berríos-Torres, S. I. et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 152, 784–791 (2017). Klevens, R. M. et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 122, 160–6 (2007). Anderson, D. J. et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 29 Suppl 1, S51-61 (2008). Bratzler, D. W. et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 70, 195–283 (2013). Gottrup, F. Prevention of surgical-wound infections. N Engl J Med 342, 202–4 (2000). Mangram, A. J., Horan, T. C., Pearson, M. L., Silver, L. C. & Jarvis, W. R. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 27, 97–132; quiz 133–4; discussion 96 (1999). Yalçin, A. N., Bakir, M., Bakici, Z., Dökmetas, I. & Sabir, N. Postoperative wound infections. J Hosp Infect 29, 305–9 (1995). Sereysky, J., Parsikia, A., Stone, M. E., Castaldi, M. & McNelis, J. Predictive factors for the development of surgical site infection in adults undergoing initial open inguinal hernia repair. Hernia 24, 173–178 (2020). Dipp Ramos, R., O’Brien, W. J., Gupta, K. & Itani, K. M. F. Incidence and Risk Factors for Long-Term Mesh Explantation Due to Infection in More than 100,000 Hernia Operation Patients. J Am Coll Surg 232, 872–880.e2 (2021). Sauerland, S., Walgenbach, M., Habermalz, B., Seiler, C. M. & Miserez, M. Laparoscopic versus open surgical techniques for ventral or incisional hernia repair. Cochrane Database Syst Rev CD007781 (2011) doi: 10.1002/14651858.CD007781.pub2 . Badia, J. M. et al. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 96, 1–15 (2017). Murray, B. W., Cipher, D. J., Pham, T. & Anthony, T. The impact of surgical site infection on the development of incisional hernia and small bowel obstruction in colorectal surgery. Am J Surg 202, 558–60 (2011). de Lissovoy, G. et al. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control 37, 387–397 (2009). Sullivan, E., Gupta, A. & Cook, C. H. Cost and Consequences of Surgical Site Infections: A Call to Arms. Surg Infect (Larchmt) 18, 451–454 (2017). Alexander, J. W., Solomkin, J. S. & Edwards, M. J. Updated recommendations for control of surgical site infections. Ann Surg 253, 1082–93 (2011). Cha, H. G., Kwon, J. G., Han, H. H., Eom, J. S. & Kim, E. K. Appropriate Prophylactic Antibiotic Use in Clean Wound Surgery Under Local Anesthesia. J Korean Med Sci 34, e135 (2019). Allegranzi, B. et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis 16, e288–e303 (2016). López-Cano, M. et al. Use of Topical Antibiotics before Primary Incision Closure to Prevent Surgical Site Infection: A Meta-Analysis. Surg Infect (Larchmt) 20, 261–270 (2019). Chen, P.-J., Hua, Y.-M., Toh, H. S. & Lee, M.-C. Topical antibiotic prophylaxis for surgical wound infections in clean and clean-contaminated surgery: a systematic review and meta-analysis. BJS Open 5, (2021). Zhang, M., Feng, H., Gao, Y., Gao, X. & Ji, Z. Effect of topical antibiotics on the prevention and management of wound infections: A meta-analysis. Int Wound J 20, 4015–4022 (2023). Heal, C. F., Banks, J. L., Lepper, P., Kontopantelis, E. & van Driel, M. L. Meta-analysis of randomized and quasi-randomized clinical trials of topical antibiotics after primary closure for the prevention of surgical-site infection. Br J Surg 104, 1123–1130 (2017). Rutten, H. J. & Nijhuis, P. H. Prevention of wound infection in elective colorectal surgery by local application of a gentamicin-containing collagen sponge. Eur J Surg Suppl 31–5 (1997). Cobb, W. S., Carbonell, A. M., Kalbaugh, C. L., Jones, Y. & Lokey, J. S. Infection risk of open placement of intraperitoneal composite mesh. Am Surg 75, 762–7; discussion 767-8 (2009). Plymale, M. A., Ragulojan, R., Davenport, D. L. & Roth, J. S. Ventral and incisional hernia: the cost of comorbidities and complications. Surg Endosc 31, 341–351 (2017). Ventral Hernia Working Group et al. Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. Surgery 148, 544–58 (2010). Cobb, W. S. et al. Open retromuscular mesh repair of complex incisional hernia: predictors of wound events and recurrence. J Am Coll Surg 220, 606–13 (2015). Nissen, A. T. et al. Health-Related Quality of Life After Ventral Hernia Repair With Biologic and Synthetic Mesh. Ann Plast Surg 82, S332–S338 (2019). Musella, M., Guido, A. & Musella, S. Collagen tampons as aminoglycoside carriers to reduce postoperative infection rate in prosthetic repair of groin hernias. Eur J Surg 167, 130–2 (2001). Praveen, S. & Rohaizak, M. Local antibiotics are equivalent to intravenous antibiotics in the prevention of superficial wound infection in inguinal hernioplasty. Asian J Surg 32, 59–63 (2009). Junge, K. et al. Improved collagen type I/III ratio at the interface of gentamicin-supplemented polyvinylidenfluoride mesh materials. Langenbecks Arch Surg 392, 465–71 (2007). Klink, C. D. et al. In vitro and in vivo characteristics of gentamicin-supplemented polyvinylidenfluoride mesh materials. J Biomed Mater Res A 100, 1195–202 (2012). Schulz, K. F., Altman, D. G., Moher, D. & CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 (2010). American Society of Anesthesiologists. ASA Physical Status Classification System. https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system (2021). Muysoms, F. E. et al. Classification of primary and incisional abdominal wall hernias. Hernia 13, 407–14 (2009). Guillaumes, S. & O’Callaghan, C. A. [Spanish adaptation of the free OxMaR software for minimization and randomization of clinical studies]. Gac Sanit 33, 395–397 (2019). Dindo, D., Demartines, N. & Clavien, P.-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240, 205–13 (2004). Itani, K. M. F. et al. Comparison of laparoscopic and open repair with mesh for the treatment of ventral incisional hernia: a randomized trial. Arch Surg 145, 322–8; discussion 328 (2010). Rogmark, P. et al. Short-term outcomes for open and laparoscopic midline incisional hernia repair: a randomized multicenter controlled trial: the ProLOVE (prospective randomized trial on open versus laparoscopic operation of ventral eventrations) trial. Ann Surg 258, 37–45 (2013). Weiner-Lastinger, L. M. et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol 41, 1–18 (2020). Luijendijk, R. W. et al. A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med 343, 392–8 (2000). Dunne, J. R., Malone, D. L., Tracy, J. K. & Napolitano, L. M. Abdominal wall hernias: risk factors for infection and resource utilization. J Surg Res 111, 78–84 (2003). Finan, K. R., Vick, C. C., Kiefe, C. I., Neumayer, L. & Hawn, M. T. Predictors of wound infection in ventral hernia repair. Am J Surg 190, 676–81 (2005). White, T. J., Santos, M. C. & Thompson, J. S. Factors affecting wound complications in repair of ventral hernias. Am Surg 64, 276–80 (1998). Grant, A. M. & EU Hernia Trialists Collaboration. Open mesh versus non-mesh repair of groin hernia: meta-analysis of randomised trials based on individual patient data [corrected]. Hernia 6, 130–6 (2002). Iqbal, C. W. et al. Long-term outcome of 254 complex incisional hernia repairs using the modified Rives-Stoppa technique. World J Surg 31, 2398–404 (2007). Cherla, D. V et al. Decreasing Surgical Site Infections after Ventral Hernia Repair: A Quality-Improvement Initiative. Surg Infect (Larchmt) 18, 780–786 (2017). Allegranzi, B. et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis 16, e276–e287 (2016). Tong, Q.-J. et al. A systematic review and meta-analysis on the use of prophylactic topical antibiotics for the prevention of uncomplicated wound infections. Infect Drug Resist 11, 417–425 (2018). Huiras, P., Logan, J. K., Papadopoulos, S. & Whitney, D. Local antimicrobial administration for prophylaxis of surgical site infections. Pharmacotherapy 32, 1006–19 (2012). McHugh, S. M., Collins, C. J., Corrigan, M. A., Hill, A. D. K. & Humphreys, H. The role of topical antibiotics used as prophylaxis in surgical site infection prevention. J Antimicrob Chemother 66, 693–701 (2011). Sadava, E. E., Krpata, D. M., Gao, Y., Novitsky, Y. W. & Rosen, M. J. Does presoaking synthetic mesh in antibiotic solution reduce mesh infections? An experimental study. J Gastrointest Surg 17, 562–8 (2013). Al-Shehri, M. Y. et al. Topical ampicillin for prophylaxis against wound infection in acute appendicitis. Ann Saudi Med 14, 233–6 (1994). Friberg, O. et al. Antibiotic concentrations in serum and wound fluid after local gentamicin or intravenous dicloxacillin prophylaxis in cardiac surgery. Scand J Infect Dis 35, 251–4 (2003). Binnebösel, M. et al. Impact of gentamicin-supplemented polyvinylidenfluoride mesh materials on MMP-2 expression and tissue integration in a transgenic mice model. Langenbecks Arch Surg 395, 413–20 (2010). Suárez-Grau, J. M. et al. Antibiotic embedded absorbable prosthesis for prevention of surgical mesh infection: experimental study in rats. Hernia 19, 187–94 (2015). Deysine, M. Infection control in a hernia clinic: 24 year results of aseptic and antiseptic measure implementation in 4,620 ‘clean cases’. Hernia 10, 25–9 (2006). Schimmer, C. et al. Gentamicin-collagen sponge reduces sternal wound complications after heart surgery: a controlled, prospectively randomized, double-blind study. J Thorac Cardiovasc Surg 143, 194–200 (2012). Guzmán Valdivia Gomez, G., Guerrero, T. S., Lluck, M. C. & Delgado, F. J. Effectiveness of collagen-gentamicin implant for treatment of ‘dirty’ abdominal wounds. World J Surg 23, 123–6; discussion 126-7 (1999). Bennett-Guerrero, E. et al. Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA 304, 755–62 (2010). Emile, S. H., Elfallal, A. H., Abdel-Razik, M. A., El-Said, M. & Elshobaky, A. A randomized controlled trial on irrigation of open appendectomy wound with gentamicin- saline solution versus saline solution for prevention of surgical site infection. Int J Surg 81, 140–146 (2020). Bennett-Guerrero, E. et al. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med 363, 1038–49 (2010). Tubre, D. J., Schroeder, A. D., Estes, J., Eisenga, J. & Fitzgibbons, R. J. Surgical site infection: the ‘Achilles Heel’ of all types of abdominal wall hernia reconstruction. Hernia 22, 1003–1013 (2018). Page, C. P. et al. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 128, 79–88 (1993). Shlaes, D. M. et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25, 584–99 (1997). Moore, R. D., Lietman, P. S. & Smith, C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155, 93–9 (1987). Bruce, J., Russell, E. M., Mollison, J. & Krukowski, Z. H. The quality of measurement of surgical wound infection as the basis for monitoring: a systematic review. J Hosp Infect 49, 99–108 (2001). Gignoux, B. et al. Incidence and risk factors for incisional hernia and recurrence: Retrospective analysis of the French national database. Colorectal Dis 23, 1515–1523 (2021). Ruiz-Tovar, J. et al. Effect of gentamicin lavage of the axillary surgical bed after lymph node dissection on drainage discharge volume. Breast 22, 874–8 (2013). Binnebösel, M. et al. Intraperitoneally applied gentamicin increases collagen content and mechanical stability of colon anastomosis in rats. Int J Colorectal Dis 24, 433–40 (2009). Vaneerdeweg, W., Hendriks, J. M., Lauwers, P. R., Ieven, M. & Eyskens, E. J. Effect of gentamicin-containing sponges on the healing of colonic anastomoses in a rat model of peritonitis. Eur J Surg 166, 959–62 (2000). Gette, M. T., Marks, J. G. & Maloney, M. E. Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol 128, 365–7 (1992). Damm, S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health Syst Pharm 68, 323–7 (2011). Gehrig, K. A. & Warshaw, E. M. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 58, 1–21 (2008). Kokotovic, D., Bisgaard, T. & Helgstrand, F. Long-term Recurrence and Complications Associated With Elective Incisional Hernia Repair. JAMA 316, 1575–1582 (2016). Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 20 Nov, 2024 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 25 Oct, 2024 Reviews received at journal 25 Oct, 2024 Reviewers agreed at journal 14 Oct, 2024 Reviews received at journal 27 Aug, 2024 Reviewers agreed at journal 04 Aug, 2024 Reviewers invited by journal 30 Jul, 2024 Editor assigned by journal 30 Jul, 2024 Editor invited by journal 29 Jul, 2024 Submission checks completed at journal 27 Jul, 2024 First submitted to journal 08 Jul, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4703140","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":342279405,"identity":"dc19ec31-a843-472a-b7bc-dd6860a9f1b3","order_by":0,"name":"Nils Jimmy Hidalgo","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAwklEQVRIiWNgGAWjYDACZuYGZgYGmwQwJ6GAKC2MIC1pCQxsIC0GRFkD1nIYooWBGC3m7IzNnwv3nM/jl+9O/PDAgEGeX+wAfi2WzYxt0jOe3S6WbOPdLAF0mOHM2Qn4tRgcZmxj5jlwO3HDMd4NIC0JBrcJa2n+zHPgHEjL5h/EammQ5jlwAKRlG9G2tAG1JCfObMvdZpFgIEGEX84fPgx0mF1iP/PZzTd/VNjI80sT0IIOJEhTPgpGwSgYBaMAOwAA5IlCcbfkakUAAAAASUVORK5CYII=","orcid":"","institution":"Hospital Clínic Barcelona","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Nils","middleName":"Jimmy","lastName":"Hidalgo","suffix":""},{"id":342279406,"identity":"62555029-6262-44c1-962c-f30ffce34301","order_by":1,"name":"Montserrat Juvany","email":"","orcid":"","institution":"Hospital del Mar","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Montserrat","middleName":"","lastName":"Juvany","suffix":""},{"id":342279408,"identity":"f5b1e776-e001-4439-8710-12cedffc95d5","order_by":2,"name":"Salvador Guillaumes","email":"","orcid":"","institution":"Hospital Clínic Barcelona","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Salvador","middleName":"","lastName":"Guillaumes","suffix":""},{"id":342279409,"identity":"643848a8-c85b-4606-a258-79baa145b167","order_by":3,"name":"Carlos Hoyuela","email":"","orcid":"","institution":"Hospital Universitario Mollet","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Carlos","middleName":"","lastName":"Hoyuela","suffix":""},{"id":342279410,"identity":"0e0c6e47-655f-4ef9-8199-2ac293989505","order_by":4,"name":"Óscar Vidal","email":"","orcid":"","institution":"Hospital Clínic Barcelona","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Óscar","middleName":"","lastName":"Vidal","suffix":""},{"id":342279411,"identity":"09bf4403-9531-44dc-af34-744e37f4dc2f","order_by":5,"name":"Miguel Pera","email":"","orcid":"","institution":"Hospital Clínic Barcelona","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Miguel","middleName":"","lastName":"Pera","suffix":""}],"badges":[],"createdAt":"2024-07-08 06:37:16","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4703140/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4703140/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-024-80112-y","type":"published","date":"2024-11-20T15:57:43+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":63802256,"identity":"099ca9f2-c729-462f-8b89-c2e64fba02c4","added_by":"auto","created_at":"2024-09-02 13:18:14","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":336444,"visible":true,"origin":"","legend":"\u003cp\u003eCONSORT flow chart for recruitment.\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4703140/v1/e367a9e93c3bcb194057b012.jpg"},{"id":69834942,"identity":"586604fb-2650-4766-9fad-f2ef1c8770e5","added_by":"auto","created_at":"2024-11-25 16:10:36","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1081669,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4703140/v1/64da7c60-81e2-4e2c-90a8-0e46442d6e0e.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Effect of topical gentamicin in preventing surgical site infection in elective incisional hernia repair: a randomized controlled trial","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eSurgical site infection (SSI) continues to be one of the most common complications of surgery despite advances in surgical technology and prevention measures, accounting for up to 20% of all healthcare-associated infections \u003csup\u003e1\u003c/sup\u003e. SSI is the second leading cause of hospital-acquired infection and remains one of the most common preventable infections today \u003csup\u003e2,3\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe estimated incidence of SSI is around 5% \u003csup\u003e4\u0026ndash;6\u003c/sup\u003e. However, this may be an underestimated rate, given that approximately 50% of SSIs is diagnosed outside the hospital after the patient has been discharged \u003csup\u003e1,7\u003c/sup\u003e. Additionally, the incidence of SSI varies greatly depending on several factors, such as the type of surgical procedure performed. In colorectal surgery, the incidence of SSI can be up to 32% \u003csup\u003e8\u003c/sup\u003e. After abdominal wall surgery, inguinal hernia infection rates range from 2.4\u0026ndash;4.9% \u003csup\u003e9,10\u003c/sup\u003e, while those of incisional hernia can reach 33% \u003csup\u003e11\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eSSI causes increased morbidity and mortality \u003csup\u003e7,12\u003c/sup\u003e, impairs the wound healing process, resulting in a higher probability of having an incisional hernia \u003csup\u003e13\u003c/sup\u003e, prolongs hospital stay \u003csup\u003e14\u003c/sup\u003e, and causes higher healthcare costs \u003csup\u003e15\u003c/sup\u003e. The incidence of infectious complications is one of the most important outcome measures in surgery, so everything possible must be done to design effective methods to reduce them.\u003c/p\u003e \u003cp\u003eAmong measures to prevent SSI, topical antibiotics have been used for decades in surgical practice \u003csup\u003e16,17\u003c/sup\u003e however, there is still controversy about their use, and there is a lack of consistent evidence on the effectiveness of this measure. The World Health Organization (WHO) guidelines do not recommend topical antibiotics before wound closure \u003csup\u003e18\u003c/sup\u003e. The Centers for Disease Control and Prevention (CDC) guidelines also advise against applying ointments, solutions, or powders to the incision site but indicate that irrigation with antibiotic agents of intra-abdominal, deep tissues, or subcutaneous remains an unresolved question \u003csup\u003e2\u003c/sup\u003e. Evidence evaluated by some meta-analyses also demonstrated that topical antibiotics before wound closure could not be recommended \u003csup\u003e19,20\u003c/sup\u003e. On the other hand, two recent meta-analyses concluded that the use of topical antibiotics probably prevents SSI compared to placebo and antiseptics, but that these results should be taken with caution due to the low number of studies used for comparison and the low statistical power from some studies \u003csup\u003e21,22\u003c/sup\u003e Overall, high-quality data supporting the use of topical antibiotics for SSI prevention is lacking; however, there may be benefits in specific procedures and populations such as joint arthroplasty, cataract surgery, spine surgery, and obese patients undergoing abdominal surgery and, specifically, colorectal resections \u003csup\u003e2,23\u003c/sup\u003e. In summary, the use of topical antibiotics cannot currently be recommended, but clinical trials evaluating their effectiveness are still necessary \u003csup\u003e19\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eSSI represents a major concern in mesh ventral hernia repair because of the risk of a devastating complication such as mesh infection that can occur in up to 7%-10% of patients \u003csup\u003e24\u003c/sup\u003e. Additionally, SSI is associated with increased morbidity, poorer quality of life, increased costs, and hernia recurrence \u003csup\u003e25\u0026ndash;28\u003c/sup\u003e. Clinical studies analyzing topical antibiotics in abdominal wall surgery are scarce, carried out mainly in inguinal hernia repair \u003csup\u003e29,30\u003c/sup\u003e, and experimental studies with good results after using prosthetic material with gentamicin \u003csup\u003e31,32\u003c/sup\u003e. Considering this, we believe conducting clinical trials on this topic is necessary.\u003c/p\u003e \u003cp\u003eThe main objective of the present trial was to evaluate the usefulness of topical gentamicin as a prophylaxis for surgical site infection in incisional hernia repair with mesh. Secondary objectives were to evaluate the incidence of other surgical site occurrences and adverse effects or complications associated with the use of topical gentamicin.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design\u003c/h2\u003e \u003cp\u003eA randomized controlled trial was conducted in patients undergoing open incisional hernia repair from March 2017 to March 2021. The study was carried out at the Hospital Plat\u0026oacute;, a basic general hospital with a high workload in abdominal wall surgery. Since 2021, it has been part of the Hospital Cl\u0026iacute;nic Barcelona, a tertiary reference center. The trial was registered in the European database of clinical trials with medicines EudraCT (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ewww.clinicaltrialsregister.eu\u003c/a\u003e\u003c/span\u003e\u003cspan address=\"http://www.clinicaltrialsregister.eu\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e) with the identifier 2018-001860-45 (04/07/2019). The manuscript was prepared following the guidelines of the CONSORT (Consolidated Standards of Reporting Trials) statement \u003csup\u003e33\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eEligibility criteria\u003c/h2\u003e \u003cp\u003eThe inclusion criteria were adults 18 years or older and elective open ventral incisional hernia repair surgery. The incisional hernia was diagnosed by clinical examination or imaging findings with ultrasound or abdominal tomography.\u003c/p\u003e \u003cp\u003eThe exclusion criteria were known allergic reaction to aminoglycosides, parastomal hernia, repair by minimally invasive surgery, performance of another concomitant surgical procedure, infection at the time of surgery, antibiotic treatment until less than 48 hours before surgery, and patients who did not wish to participate in the study.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003ePreoperative and intraoperative data collection\u003c/h2\u003e \u003cp\u003eFor each patient, demographic data (age, sex, body mass index), comorbidities (diabetes mellitus, heart disease, chronic lung disease, kidney disease, liver disease, obesity), use of immunosuppressive medication or steroids, tobacco consumption, anesthetic risk using the American Society of Anesthesiologists (ASA) classification \u003csup\u003e34\u003c/sup\u003e, and presence of recurrent incisional hernia.\u003c/p\u003e \u003cp\u003eThe intraoperative data recorded were operative time, hernia size, hernia size classification according to the European Hernia Society (EHS) \u003csup\u003e35\u003c/sup\u003e, location of the hernia according to the EHS classification \u003csup\u003e35\u003c/sup\u003e, size of the mesh used, abdominal wall plane where the mesh was placed, associated intestinal resection, and drain placement.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eRandom sequence generation and blinding\u003c/h2\u003e \u003cp\u003eRandomization was done after the preoperative visit, and the patient's consent was obtained to participate in the trial. Randomization was performed with the Spanish version of the free and open-source OxMaR system software available online \u003csup\u003e36\u003c/sup\u003e. Restricted randomization was performed through minimization to assign patients to groups. Criteria for minimization were sex (male, female), age, diabetes mellitus, and body mass index (BMI).\u003c/p\u003e \u003cp\u003ePatients were randomly assigned to one of two groups: gentamicin group and saline solution (placebo) group.\u003c/p\u003e \u003cp\u003eThe study was double-blind, where the patients did not know the group to which they were assigned, and the outcome assessors were also unaware of the treatment groups. The operating surgeons and operating room nurses were aware of the nature of the study and the assignment of patients to each group at the time of surgery.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eSurgical procedure\u003c/h2\u003e \u003cp\u003eProcedures were performed under general or spinal anesthesia with patients lying supine. A dose of 2 g of intravenous cefazolin was administered 30 minutes before surgery, and 600 mg of intravenous clindamycin was administered to patients with beta-lactam allergy. All procedures were performed using an open approach by two surgeons with experience in abdominal wall surgery. Before starting surgery, the skin was prepared by washing with chlorhexidine soap and painting the surgical field with 2% alcoholic chlorhexidine.\u003c/p\u003e \u003cp\u003eA spindle incision of the skin was made with the excision of the scar from the previous surgery, the subcutaneous cellular tissue opening, identification, and dissection of the hernial sac. To repair the hernia defect, a 60 g/m2 monofilament polypropylene mesh with a 1.15 mm pore was used, placed according to the characteristics of the hernia at the preperitoneal, retromuscular or supra aponeurotic level. The meshes were fixed with a poly-4-hydroxybutyrate monofilament absorbable synthetic suture. The aponeurosis closure was performed with a continuous suture according to the small bite technique using absorbable monofilament synthetic suture of poly-4-hydroxybutyrate, the closure of the subcutaneous cellular tissue with absorbable multifilament synthetic suture of polyglactin 910 and the skin with a continuous intradermal suture with absorbable monofilament synthetic of polyester Glycomer 631. Depending on the characteristics of the hernia and the surgeon's choice, a closed system drain was placed in the retromuscular or subcutaneous space, inserted through an incision in the skin far from the surgical wound.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eStudy intervention\u003c/h2\u003e \u003cp\u003eAfter placing the mesh in the gentamicin group, each layer of the abdominal wall was irrigated with 160 mg of gentamicin diluted in 500 ml of normal saline solution (0.9% NaCl). In the saline solution (placebo) group, each layer of the abdominal wall was irrigated with 500 ml of normal saline solution. After the intervention, the surgical wound was closed.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003ePostoperative care\u003c/h2\u003e \u003cp\u003eIn the hospitalization room, vital signs and drainage (if present) were evaluated. Analgesia during admission was achieved with paracetamol 1g every eight hours and dexketoprofen every eight hours intravenously. Systemic or topical antibiotics were not routinely administered postoperatively. The wounds were examined every day by a surgeon until discharge. Drains were removed before discharge if the discharge was scant and had non-haematic characteristics. The surgical wound dressings were removed on the second postoperative day, and showering was permitted. Oral analgesia at discharge was with paracetamol and dexketoprofen.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eFollow-up\u003c/h2\u003e \u003cp\u003ePatient follow-up was carried out in outpatient surgery consultations at seven days, 30 days, six months, and 12 months after the intervention. The surgical outcome was evaluated by a surgeon who was not involved in the surgery and was unaware of the group assignment. At each visit, wound healing was assessed, and complications, including SSI, were recorded. If SSI with discharge was detected, wound cultures were taken.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003ePrimary outcome\u003c/h2\u003e \u003cp\u003eThe study's primary outcome was the incidence of SSI (superficial, deep, and organ/space), which was defined according to the criteria developed by the CDC \u003csup\u003e7\u003c/sup\u003e. These criteria define superficial SSI as occurring up to 30 days after surgery and affecting only the skin or subcutaneous tissue. Deep SSI was defined as one that involves deep soft tissues such as fascia and muscle that occur up to one year after surgery if a prosthesis is placed. Organ/space infection was defined as infection deeper than the fascia or muscular wall, which has been opened or manipulated during the surgical procedure.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eSecondary outcomes\u003c/h2\u003e \u003cp\u003eThe incidence of other surgical site occurrences such as seroma (bag of sterile, clear serous fluid at the incision site), hematoma (accumulation of blood or clots in the surgical wound), wound dehiscence, or enterocutaneous fistula was analyzed \u003csup\u003e26\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe isolation of microorganisms in surgical wound samples in patients with SSI and the treatment performed in patients with SSI, such as systemic antibiotics, drainage of abscesses, or need for reintervention to remove the mesh, were analyzed.\u003c/p\u003e \u003cp\u003eOther outcomes analyzed were postoperative complications outside the surgical site, postoperative complications according to the Clavien-Dindo classification \u003csup\u003e37\u003c/sup\u003e, hospital stay, mortality 30 days after surgery, and hernia recurrence after one year of follow-up.\u003c/p\u003e \u003cp\u003eAdverse events that were potentially attributable to the study antibiotic were also reported. An independent data and safety monitoring committee monitored the trial continuously.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eSample size calculation\u003c/h2\u003e \u003cp\u003eThe primary endpoint for calculating the required sample size was the incidence of surgical wound infection. Based on the results of two clinical trials \u003csup\u003e38,39\u003c/sup\u003e, we assumed an SSI rate of 23% in the group without topical gentamicin and 6% in the group with topical gentamicin. The sample size calculated was 146 patients to identify this difference with an alpha error of 0.05 and a power of 0.8. The dropout rate was expected to be 5%; therefore, we aimed for a total sample size of 154 patients. Due to the low dropout rate, we ended recruitment after 150 patients. The sample size was calculated with Gpower 3.1 software.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eStatistic analysis\u003c/h2\u003e \u003cp\u003eCategorical variables were analyzed using Pearson's Chi-square or Fisher's exact tests. For continuous variables, the normality of the data distribution was tested using the Kolmogorov-Smirnov test. The student t-test was used to analyze differences in continuous variables with a normal distribution, and the non-parametric Mann-Whitney U test was used to analyze continuous variables with a non-normal distribution.\u003c/p\u003e \u003cp\u003eA level of p\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered to establish statistical significance. A per-protocol approach was used for data analysis. Statistical analyses were performed using IBM SPSS 27.0 software (Armonk, NY: IBM Corp).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eEthics\u003c/h2\u003e \u003cp\u003e The protocol of this trial was approved by the drug research ethics committee of the Catalan Union of Hospitals Foundation, and its implementation was authorized by the Spanish Agency for Medicines and Health Products. All eligible patients gave written informed consent. This study was performed in accordance with the Declaration of Helsinki.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eRecruited patients\u003c/h2\u003e \u003cp\u003eFrom March 2017 to March 2021, 171 patients admitted for elective incisional hernia repair met inclusion criteria. Nineteen patients were excluded from the study due to refusal to participate, and two patients were due to a history of allergy to aminoglycosides. Finally, 150 patients were randomized; 75 were assigned to the gentamicin group and 75 to the saline solution group. One patient in the gentamicin group and three in the saline solution group were lost to follow-up. Finally, data from 146 patients were included for analysis: 74 in the gentamicin group and 72 in the saline solution group. Figure\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows the recruitment flow chart according to CONSORT recommendations \u003csup\u003e33\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eBaseline characteristics of the study groups\u003c/h2\u003e \u003cp\u003eThe mean age was 67.2\u0026thinsp;\u0026plusmn;\u0026thinsp;11.3 in the gentamicin group and 65.36\u0026thinsp;\u0026plusmn;\u0026thinsp;14.08 in the saline solution group, with no significant differences between both groups (p\u0026thinsp;=\u0026thinsp;0.384). The two groups had no significant differences regarding sex, BMI, comorbidities analyzed, anesthetic risk (ASA), and recurrent hernia (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline characteristics of study groups\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical gentamicin (N\u0026thinsp;=\u0026thinsp;74)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTopical saline solution (N\u0026thinsp;=\u0026thinsp;72)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge, Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e67.2\u0026thinsp;\u0026plusmn;\u0026thinsp;11.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65.36\u0026thinsp;\u0026plusmn;\u0026thinsp;14.08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.384\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSex, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.517\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e31 (41.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e34 (47.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e43 (58.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38 (52.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBMI (Kg/m\u003csup\u003e2\u003c/sup\u003e), Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e30.29\u0026thinsp;\u0026plusmn;\u0026thinsp;5.74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e30.12\u0026thinsp;\u0026plusmn;\u0026thinsp;5.04\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.84\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComorbidities, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDiabetes mellitus\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13 (17.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (13.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.542\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHeart disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13 (17.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10 (13.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.542\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eChronic pulmonary disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (12.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (11.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.843\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRenal disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (4.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.117\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLiver disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.497\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eObesity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e37 (\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e38 (52.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.037\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTobacco use\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9 (12.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (11.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.843\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSteroid or immunosuppressant use\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (4.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.679\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eASA, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.377\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eASA I\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (8.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.53\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eASA II\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e57 (77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e48 (66.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.164\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eASA III\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e13 (17.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18 (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.272\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecurrent hernia, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16 (21.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18 (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.629\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cem\u003eSD: standard deviation, BMI: body mass index, ASA: American Society of Anesthesiologists classification.\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eCharacteristics of the hernia and surgery\u003c/h2\u003e \u003cp\u003eThe mean operating time was 71.84\u0026thinsp;\u0026plusmn;\u0026thinsp;36.19 min in the gentamicin group and 77.22\u0026thinsp;\u0026plusmn;\u0026thinsp;41.52 min in the saline solution group, with no significant differences between both groups (p\u0026thinsp;=\u0026thinsp;0.402). When analyzing the size of the hernia, location of the hernia, mesh size, plane of mesh placement, need for intestinal resection, and use of drainage between both groups, no statistically significant differences were observed (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eIntraoperative data of study groups\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical gentamicin (N\u0026thinsp;=\u0026thinsp;74)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTopical saline solution (N\u0026thinsp;=\u0026thinsp;72)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOperative time (min), Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e71.84\u0026thinsp;\u0026plusmn;\u0026thinsp;36.19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e77.22\u0026thinsp;\u0026plusmn;\u0026thinsp;41.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.402\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHernia size (cm), Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHernia length\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6.95\u0026thinsp;\u0026plusmn;\u0026thinsp;5.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7.18\u0026thinsp;\u0026plusmn;\u0026thinsp;5.48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.964\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHernia width\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4.89\u0026thinsp;\u0026plusmn;\u0026thinsp;2.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.13\u0026thinsp;\u0026plusmn;\u0026thinsp;2.96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.496\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHernia size classification (EHS), N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.839\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEHS W1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26 (35.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22 (30.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEHS W2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e44 (59.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46 (63.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEHS W3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (5.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4 (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHernia localization, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.078\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedial\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e64 (86.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e54 (\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLateral\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e10 (13.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18 (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMesh size (cm\u003csup\u003e2\u003c/sup\u003e), Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e220.93\u0026thinsp;\u0026plusmn;\u0026thinsp;344.51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e254.56\u0026thinsp;\u0026plusmn;\u0026thinsp;279.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.129\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMesh placement, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.578\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOnlay\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27 (36.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26 (36.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRetromuscular\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e39 (52.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e41 (56.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePreperitoneal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOnlay\u0026thinsp;+\u0026thinsp;Retromuscular\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7 (9.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (4.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIntestinal resection, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDrain use, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50 (67.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47 (65.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.77\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cem\u003eSD: standard deviation, EHS: European Hernia Society\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eOutcomes of both groups\u003c/h2\u003e \u003cp\u003eThe incidence of SSI in the entire sample analyzed was 9.6%. SSI was observed in six patients (8.1%) in the gentamicin group and eight patients (11.1%) in the saline solution group, with no significant differences (p\u0026thinsp;=\u0026thinsp;0.538) between both groups. Six patients in the gentamicin group had superficial infections, seven in the saline solution group had superficial infections, and one had a deep infection (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). No organ/space infection was reported in any of the groups.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eOutcomes of study groups\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical gentamicin (N\u0026thinsp;=\u0026thinsp;74)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTopical Saline solution (N\u0026thinsp;=\u0026thinsp;72)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003ep-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSurgical site occurrence, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAny surgical site occurrence\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e18 (24.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e21 (29.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.509\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSeroma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8 (10.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13 (18.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.212\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHematomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.681\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWound dehiscence\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (6.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.272\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSurgical site infection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (8.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (11.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.538\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSuperficial surgical site infection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (8.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (9.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.732\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDeep surgical site infection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.493\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMesh infection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.493\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCultures performed\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (9.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.206\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePositive culture\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (9.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.095\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSurgical site infection treatment, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAntibiotic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4 (5.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.717\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAntibiotic and abscess drainage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (4.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (4.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAntibiotic, abscess drainage, and remove mesh\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.493\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOther complications, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (4.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eClavien Dindo, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.564\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (1.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (5.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (4.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLength of stay (days), Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.32\u0026thinsp;\u0026plusmn;\u0026thinsp;2.73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.86\u0026thinsp;\u0026plusmn;\u0026thinsp;4.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.465\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMortality 30 days, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHernia recurrence, N (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (2.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (8.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.163\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cem\u003eSD: standard deviation\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eNo statistically significant differences were observed in the presentation of seroma, hematoma, and surgical wound dehiscence between both groups. Some complication of the surgical wound (surgical site infection, seroma, hematoma, or wound dehiscence) was observed in 18 patients (24.3%) in the gentamicin group and 21 patients (29.2%) in the saline solution group, without significant differences (p\u0026thinsp;=\u0026thinsp;0.509). Furthermore, no adverse effects or allergic reactions were reported.\u003c/p\u003e \u003cp\u003eOther complications not related to the surgical wound occurred in seven patients: two patients with acute urinary retention, one patient with cardiac arrhythmias, one patient with bronchospasm, one patient with pneumonia, one patient with confusional syndrome, and one patient with paralytic ileus. No significant differences were observed between both groups.\u003c/p\u003e \u003cp\u003eNo significant differences were also observed between both groups when comparing postoperative complications according to the Clavien-Dindo classification, hospital stay, 30-day mortality, and hernia recurrence at one year of follow-up.\u003c/p\u003e \u003cp\u003eNo adverse events potentially attributable to the use of the topical antibiotic were reported in patients in the gentamicin group.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eDetails of infected patients\u003c/h2\u003e \u003cp\u003eAll surgical site infections were diagnosed after hospital discharge. In the gentamicin group, three patients were treated with oral antibiotics alone, and three patients required abscess drainage in addition to the antibiotic. In the saline solution group, four patients were treated with oral antibiotics only, three patients with oral antibiotics and abscess drainage, and one patient also required mesh removal (Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eSurgical wound cultures were performed in 10 patients, and pathogenic microorganisms were isolated in 2 patients in the gentamicin group and seven in the saline solution group. Bacteria resistant to gentamicin were Enterococcus faecalis (in 1 of 2 isolates) and Pseudomonas aeruginosa (in 1 of 2 isolates). Gentamicin-resistant bacteria were isolated in two patients in the gentamicin group. The bacteria isolated in the samples and the antibiotic resistance in both groups are detailed in Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eType of bacteria isolated in cultures from the infected surgical site.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCase\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAllocated intervention\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBacteria isolated (R: resistant antibiotic)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical gentamicin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eEnterococcus faecalis\u003c/em\u003e (R: Erythromycin, Tetracycline, Cotrimoxazole, Fosfomycin, Gentamicin)\u003c/p\u003e \u003cp\u003e\u003cem\u003ePeptoniphilus harei\u003c/em\u003e (R: Erythromycin, Clindamycin, Tetracycline)\u003c/p\u003e \u003cp\u003e\u003cem\u003eActinomyces turicensis\u003c/em\u003e (R: Metronidazole)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical gentamicin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003ePseudomonas aeruginosa\u003c/em\u003e (R: Gentamicin)\u003c/p\u003e \u003cp\u003e\u003cem\u003eCitrobacter freundii\u003c/em\u003e (R: Ampicillin, Amoxicillin/clavulanic, Cephalothin)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical gentamicin\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNegative\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eEnterococcus faecalis\u003c/em\u003e (R: Erythromycin, Tetracycline, Cotrimoxazole, Fosfomycin)\u003c/p\u003e \u003cp\u003e\u003cem\u003eCitrobacter koseri\u003c/em\u003e (R: Ampicillin)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eStaphylococcus aureus\u003c/em\u003e (R: Penicillin)\u003c/p\u003e \u003cp\u003e\u003cem\u003ePseudomonas aeruginosa\u003c/em\u003e (R: Ampicillin/sulbactam, Cefotaxime, Minocycline, Cotrimoxazole)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eEscherichia coli\u003c/em\u003e (R: Ampicillin, Piperacillin, Ciprofloxacin, Levofloxacin)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eSerratia marcescens\u003c/em\u003e (R: Ampicillin, Amoxicillin/clavulanic, Cefuroxime, Tobramycin)\u003c/p\u003e \u003cp\u003e\u003cem\u003eStaphylococcus aureus\u003c/em\u003e (R: Erythromycin, Clindamycin,\u003c/p\u003e \u003cp\u003e\u003cem\u003eStreptococcus agalactiae\u003c/em\u003e (R: Tetracycline)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eProteus mirabilis\u003c/em\u003e (R: Nalidixic acid, Fosfomycin)\u003c/p\u003e \u003cp\u003e\u003cem\u003eEnterococcus faecium\u003c/em\u003e (R: Penicillin, Ampicillin, Cefuroxime, Imipenem, Ciprofloxacin, Levofloxacin, Erythromycin, Clindamycin, Cotrimoxazole, Streptomycin, Kanamycin)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eProteus mirabilis\u003c/em\u003e (R: Tigecycline)\u003c/p\u003e \u003cp\u003e\u003cem\u003eStaphylococcus aureus\u003c/em\u003e (R: none)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTopical saline solution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003eStaphylococcus aureus\u003c/em\u003e (R: Penicillin)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eIn this randomized controlled trial, topical gentamicin before wound closure of incisional hernia repair with mesh did not significantly reduce the incidence of SSI. There were also no significant differences in the incidence of other local complications or adverse effects due to topical gentamicin.\u003c/p\u003e \u003cp\u003eSSI is a common postoperative complication associated with worse outcomes and higher costs \u003csup\u003e12,15\u003c/sup\u003e. In a recent study in the U.S., SSI was the most common infection associated with medical care, representing 42% of these infections \u003csup\u003e40\u003c/sup\u003e. The incidence of SSI varies depending on several factors, such as the type of surgical procedures, the context in which the operations are performed, patient comorbidities, surveillance criteria used, and the quality of data collection.\u003c/p\u003e \u003cp\u003eOverall, the incidence of SSI in clean surgical procedures is only 2%. In comparison, reported rates for wall reconstruction procedures range from 2.4\u0026ndash;4.9% in inguinal hernias \u003csup\u003e9,10\u003c/sup\u003e, between 4% and 16% in ventral hernias \u003csup\u003e41\u0026ndash;44\u003c/sup\u003e and 23\u0026ndash;33% in incisional hernias \u003csup\u003e11,38\u003c/sup\u003e. Although the presence of prosthetic mesh does not increase the incidence of infection \u003csup\u003e45\u003c/sup\u003e, SSI after hernia repair with mesh is a difficult complication to solve and is associated with high morbidity, occasionally requiring reintervention for removal of the infected mesh, increases the risk of hernia recurrence and increases healthcare costs \u003csup\u003e27,41,46\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eImplementation of evidence-based protocols can prevent up to 50\u0026ndash;60% of all SSIs \u003csup\u003e2,4,47\u003c/sup\u003e. The WHO and the CDC have developed guidelines for preventing SSIs \u003csup\u003e2,18,48\u003c/sup\u003e. Some practices to prevent SSI include adequate preoperative preparation, sterilization of the surgical site with antiseptics, proper surgical technique, and administration of prophylactic antibiotics \u003csup\u003e4,7\u003c/sup\u003e. The incidence of SSI in our study was 9.6% in the entire sample analyzed, lower than in previous years in our center, probably because conducting the clinical trial required stricter follow-up of these guidelines.\u003c/p\u003e \u003cp\u003eAmong the measures to reduce the incidence of SSI after surgery, topical antibiotics have been proposed. However, the evidence is currently low quality, so its efficacy remains uncertain \u003csup\u003e20,49\u003c/sup\u003e and is generally reserved for at-risk patients (e.g. diabetes, immunosuppression, obesity) or high-risk procedures (e.g clean-contaminated procedures, colorectal surgery, implantation of prosthetic materials) \u003csup\u003e5,50\u003c/sup\u003e. Commonly used antibiotics are beta-lactams, cephalosporins, aminoglycosides, glycopeptides, chloramphenicol, and bacitracin \u003csup\u003e51\u0026ndash;53\u003c/sup\u003e with different methods and doses of administration. To carry out this clinical trial, we chose gentamicin because it is effective against gram-negative and gram-positive bacteria such as staphylococci (S. aureus and S. epidermidis) because the local concentration achieved could be sufficient to exert a potential effect against resistant species and because it presents limited systemic toxicity \u003csup\u003e54\u003c/sup\u003e. Furthermore, favorable results have been described with topical gentamicin in experimental studies with mesh \u003csup\u003e32,55,56\u003c/sup\u003e and clinical studies performed in inguinal hernia repair with mesh \u003csup\u003e29,57\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eOur results show a lower proportion of SSIs in the gentamicin group; however, this difference was not statistically significant. Previous clinical trials conducted in inguinal hernia surgery \u003csup\u003e29\u003c/sup\u003e, cardiothoracic surgery \u003csup\u003e58\u003c/sup\u003e and colorectal surgery \u003csup\u003e23,59\u003c/sup\u003e found a significant reduction in SSI. In these studies, unlike our clinical trial, gentamicin implants or sponges were used, which could favor a longer release of the antibiotic. However, other clinical trials have shown that the use of topical gentamicin, even in the form of gentamicin sponge implantation, does not produce a relevant reduction in the rate of SSI \u003csup\u003e30,60\u0026ndash;62\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eFew studies analyze SSI rates, differentiating them into superficial and deep. A clinical trial carried out in patients undergoing sternotomy compared the results of using a sponge with gentamicin and a sponge with placebo, observing that the rate of superficial infection was similar in both groups; however, the rate of deep infection was reduced in the group with gentamicin \u003csup\u003e58\u003c/sup\u003e. Our study did not find significant differences in superficial or deep infection between the gentamicin and saline solution (placebo) groups. The importance of having information about deep infections in abdominal wall repair surgery is the associated risk of mesh infection. An estimated incidence of mesh infection is between 6% and 10% for incisional hernia repair \u003csup\u003e24\u003c/sup\u003e. In our study, only one patient with mesh infection was identified as belonging to the saline solution group and who required reintervention for mesh removal during study follow-up. The low incidence of mesh infection in our sample could be explained by the selection of patients for randomization, where we excluded parastomal hernias, emergency surgeries, and the presence of active infection.\u003c/p\u003e \u003cp\u003eThe bacteria most associated with SSI are Staphylococcus aureus (30%), followed by coagulase-negative staphylococcus (13.7%), enterococcus species (11.2%), and Escherichia coli (9.6%) \u003csup\u003e63\u003c/sup\u003e. Most SSIs are caused by microorganisms at the incision site and introduced during surgery. The contaminating germ can come from the patient's flora or a hospital-transmitted germ. The hospital microbial environment, medical conditions, and patient-specific risk factors determine the pathogenic microorganism and the risk of infection \u003csup\u003e64\u003c/sup\u003e. In our sample, the most frequently isolated bacteria were Staphylococcus aureus in four patients, Enterococcus faecalis in two patients, and Pseudomonas aeruginosa in two.\u003c/p\u003e \u003cp\u003eExcessive or unnecessary exposure to antibiotics is the cause of increasing resistance to these drugs \u003csup\u003e65\u003c/sup\u003e. A possible adverse effect of topical antibiotics is the risk of increasing resistance; for this reason, the WHO guidelines do not recommend their use \u003csup\u003e2,18\u003c/sup\u003e. However, the real risk of antibiotic resistance after local application has not yet been quantified, and its use must be weighed in situations where the benefit may outweigh the risk, such as in procedures with a high infection rate or devastating infectious complications. In our study, bacteria resistant to gentamicin were isolated in two patients belonging to the gentamicin group, which could be related to its local use. Furthermore, it should be considered that all patients received a prophylactic dose of intravenous cephalosporin, which may influence the microorganisms isolated in the cultures and resistance.\u003c/p\u003e \u003cp\u003eThe results of comparing topical prophylaxis with systemic prophylaxis and whether there is a synergistic effect when using local and systemic prophylaxis are not yet known with certainty. An argument favoring topical prophylaxis is that it allows a higher antibiotic concentration at the wound level. In contrast, the blood concentration remains low, reducing complications such as ototoxicity and nephrotoxicity associated with gentamicin \u003csup\u003e66\u003c/sup\u003e. However, the greatest disadvantage of topical prophylaxis is that it occurs after making the incision, while the recommendation to reduce SSI is that there should be adequate concentrations of the antibiotic at the surgical site when starting the incision \u003csup\u003e4,7\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eSurgical site occurrences are a quality measure of hospitals and surgeons \u003csup\u003e67\u003c/sup\u003e, which cause considerable morbidity, increase costs, and are associated with an increased risk of hernia recurrence \u003csup\u003e68\u003c/sup\u003e. The effect of topical gentamicin on developing other surgical site occurrences and SSI has also been described in the literature. A clinical trial in which gentamicin lavage of the axillary dissection site was performed after lymph node excision did not observe a significant reduction in the incidence of seroma \u003csup\u003e69\u003c/sup\u003e. Experimental studies have also been conducted on the effect of gentamicin on healing with contradictory results \u003csup\u003e70,71\u003c/sup\u003e. Our results do not show statistically significant differences in the presentation of the surgical wound's seroma, hematoma, or dehiscence.\u003c/p\u003e \u003cp\u003eIn this clinical trial, no adverse reactions related to the use of topical gentamicin were reported. The adverse reactions described using topical antibiotics vary from contact dermatitis in dermatological surgery to intraoperative anaphylactic shock \u003csup\u003e72,73\u003c/sup\u003e. The incidence of adverse reactions related to topical antibiotics is low \u003csup\u003e72,74\u003c/sup\u003e however, few studies have addressed this issue, and the pharmacokinetics of the administered antibiotics are not well reported, so the exact risk is still unknown.\u003c/p\u003e \u003cp\u003eThe limitations of this clinical trial include the fact that it was a study conducted in a single hospital, which reduces its external validity. One-year follow-up may not be sufficient to detect rare complications associated with surgical mesh that may occur up to five years after incisional hernia repair \u003csup\u003e75\u003c/sup\u003e. However, since the trial's primary objective is to determine the rate of SSI, the follow-up time of this study is sufficient to meet the criteria defining SSI \u003csup\u003e7\u003c/sup\u003e. Based on data from previous clinical trials, the estimated incidence of SSI for the placebo group was higher than the real incidence detected in this study, which influenced the calculation of the sample size and, therefore, the power. Among the strengths of this study is the inherent characteristic of a clinical trial that allows selection biases to be reduced. Factors associated with the development of SSI such as age, obesity, diabetes mellitus, chronic obstructive pulmonary disease, use of steroids, immunosuppressants, smoking, prolonged operative time, location of mesh placement, mesh size, and associated intestinal resection \u003csup\u003e42\u0026ndash;44\u003c/sup\u003e, were distributed evenly in both groups analyzed. Furthermore, this study is one of the first clinical trials to analyze the use of topical gentamicin to prevent SSI in incisional hernia surgery.\u003c/p\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eIn this clinical trial, the use of topical gentamicin in incisional hernia repair with mesh did not significantly reduce the incidence of SSI. Topical gentamicin did not significantly change the proportion of other surgical site complications. It is still necessary to carry out more studies that analyze the benefits of using topical antibiotics in preventing SSI, the risk of resistance, the pharmacokinetics of their topical application, and possible adverse effects.\u003c/p\u003e "},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability\u003cbr\u003e\u0026nbsp;\u003c/strong\u003eThe trial protocol and datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions:\u0026nbsp;\u003cbr\u003e\u0026nbsp;\u003c/strong\u003eNJ.H: project development, data collection and analysis, manuscript writing and editing. M.J: project development, data collection and analysis, manuscript editing. S.G: project development, data analysis, manuscript writing and editing. C.H: data collection, manuscript editing. O.V: data analysis, manuscript editing. M.P: data analysis, manuscript writing and editing. All authors reviewed and approved the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests:\u003c/strong\u003e The authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional information\u003cp\u003eCorrespondence\u0026nbsp;\u003c/strong\u003eand requests for materials should be addressed to NJ.H.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMagill, S. S. \u003cem\u003eet al.\u003c/em\u003e Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370, 1198\u0026ndash;208 (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBerr\u0026iacute;os-Torres, S. I. \u003cem\u003eet al.\u003c/em\u003e Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 152, 784\u0026ndash;791 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKlevens, R. M. \u003cem\u003eet al.\u003c/em\u003e Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 122, 160\u0026ndash;6 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAnderson, D. J. \u003cem\u003eet al.\u003c/em\u003e Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 29 Suppl 1, S51-61 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBratzler, D. W. \u003cem\u003eet al.\u003c/em\u003e Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 70, 195\u0026ndash;283 (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGottrup, F. Prevention of surgical-wound infections. N Engl J Med 342, 202\u0026ndash;4 (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMangram, A. J., Horan, T. C., Pearson, M. L., Silver, L. C. \u0026amp; Jarvis, W. R. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 27, 97\u0026ndash;132; quiz 133\u0026ndash;4; discussion 96 (1999).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYal\u0026ccedil;in, A. N., Bakir, M., Bakici, Z., D\u0026ouml;kmetas, I. \u0026amp; Sabir, N. Postoperative wound infections. J Hosp Infect 29, 305\u0026ndash;9 (1995).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSereysky, J., Parsikia, A., Stone, M. E., Castaldi, M. \u0026amp; McNelis, J. Predictive factors for the development of surgical site infection in adults undergoing initial open inguinal hernia repair. Hernia 24, 173\u0026ndash;178 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDipp Ramos, R., O\u0026rsquo;Brien, W. J., Gupta, K. \u0026amp; Itani, K. M. F. Incidence and Risk Factors for Long-Term Mesh Explantation Due to Infection in More than 100,000 Hernia Operation Patients. J Am Coll Surg 232, 872\u0026ndash;880.e2 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSauerland, S., Walgenbach, M., Habermalz, B., Seiler, C. M. \u0026amp; Miserez, M. Laparoscopic versus open surgical techniques for ventral or incisional hernia repair. Cochrane Database Syst Rev CD007781 (2011) doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/14651858.CD007781.pub2\u003c/span\u003e\u003cspan address=\"10.1002/14651858.CD007781.pub2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBadia, J. M. \u003cem\u003eet al.\u003c/em\u003e Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 96, 1\u0026ndash;15 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMurray, B. W., Cipher, D. J., Pham, T. \u0026amp; Anthony, T. The impact of surgical site infection on the development of incisional hernia and small bowel obstruction in colorectal surgery. Am J Surg 202, 558\u0026ndash;60 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ede Lissovoy, G. \u003cem\u003eet al.\u003c/em\u003e Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control 37, 387\u0026ndash;397 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSullivan, E., Gupta, A. \u0026amp; Cook, C. H. Cost and Consequences of Surgical Site Infections: A Call to Arms. Surg Infect (Larchmt) 18, 451\u0026ndash;454 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlexander, J. W., Solomkin, J. S. \u0026amp; Edwards, M. J. Updated recommendations for control of surgical site infections. Ann Surg 253, 1082\u0026ndash;93 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCha, H. G., Kwon, J. G., Han, H. H., Eom, J. S. \u0026amp; Kim, E. K. Appropriate Prophylactic Antibiotic Use in Clean Wound Surgery Under Local Anesthesia. J Korean Med Sci 34, e135 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAllegranzi, B. \u003cem\u003eet al.\u003c/em\u003e New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis 16, e288\u0026ndash;e303 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eL\u0026oacute;pez-Cano, M. \u003cem\u003eet al.\u003c/em\u003e Use of Topical Antibiotics before Primary Incision Closure to Prevent Surgical Site Infection: A Meta-Analysis. Surg Infect (Larchmt) 20, 261\u0026ndash;270 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen, P.-J., Hua, Y.-M., Toh, H. S. \u0026amp; Lee, M.-C. Topical antibiotic prophylaxis for surgical wound infections in clean and clean-contaminated surgery: a systematic review and meta-analysis. BJS Open 5, (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang, M., Feng, H., Gao, Y., Gao, X. \u0026amp; Ji, Z. Effect of topical antibiotics on the prevention and management of wound infections: A meta-analysis. Int Wound J 20, 4015\u0026ndash;4022 (2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeal, C. F., Banks, J. L., Lepper, P., Kontopantelis, E. \u0026amp; van Driel, M. L. Meta-analysis of randomized and quasi-randomized clinical trials of topical antibiotics after primary closure for the prevention of surgical-site infection. Br J Surg 104, 1123\u0026ndash;1130 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRutten, H. J. \u0026amp; Nijhuis, P. H. Prevention of wound infection in elective colorectal surgery by local application of a gentamicin-containing collagen sponge. Eur J Surg Suppl 31\u0026ndash;5 (1997).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCobb, W. S., Carbonell, A. M., Kalbaugh, C. L., Jones, Y. \u0026amp; Lokey, J. S. Infection risk of open placement of intraperitoneal composite mesh. Am Surg 75, 762\u0026ndash;7; discussion 767-8 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePlymale, M. A., Ragulojan, R., Davenport, D. L. \u0026amp; Roth, J. S. Ventral and incisional hernia: the cost of comorbidities and complications. Surg Endosc 31, 341\u0026ndash;351 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVentral Hernia Working Group \u003cem\u003eet al.\u003c/em\u003e Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. Surgery 148, 544\u0026ndash;58 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCobb, W. S. \u003cem\u003eet al.\u003c/em\u003e Open retromuscular mesh repair of complex incisional hernia: predictors of wound events and recurrence. J Am Coll Surg 220, 606\u0026ndash;13 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNissen, A. T. \u003cem\u003eet al.\u003c/em\u003e Health-Related Quality of Life After Ventral Hernia Repair With Biologic and Synthetic Mesh. Ann Plast Surg 82, S332\u0026ndash;S338 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMusella, M., Guido, A. \u0026amp; Musella, S. Collagen tampons as aminoglycoside carriers to reduce postoperative infection rate in prosthetic repair of groin hernias. Eur J Surg 167, 130\u0026ndash;2 (2001).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePraveen, S. \u0026amp; Rohaizak, M. Local antibiotics are equivalent to intravenous antibiotics in the prevention of superficial wound infection in inguinal hernioplasty. Asian J Surg 32, 59\u0026ndash;63 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJunge, K. \u003cem\u003eet al.\u003c/em\u003e Improved collagen type I/III ratio at the interface of gentamicin-supplemented polyvinylidenfluoride mesh materials. Langenbecks Arch Surg 392, 465\u0026ndash;71 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKlink, C. D. \u003cem\u003eet al.\u003c/em\u003e In vitro and in vivo characteristics of gentamicin-supplemented polyvinylidenfluoride mesh materials. J Biomed Mater Res A 100, 1195\u0026ndash;202 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchulz, K. F., Altman, D. G., Moher, D. \u0026amp; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmerican Society of Anesthesiologists. ASA Physical Status Classification System. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system\u003c/span\u003e\u003cspan address=\"https://www.asahq.org/standards-and-guidelines/asa-physical-status-classification-system\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuysoms, F. E. \u003cem\u003eet al.\u003c/em\u003e Classification of primary and incisional abdominal wall hernias. Hernia 13, 407\u0026ndash;14 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuillaumes, S. \u0026amp; O\u0026rsquo;Callaghan, C. A. [Spanish adaptation of the free OxMaR software for minimization and randomization of clinical studies]. Gac Sanit 33, 395\u0026ndash;397 (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDindo, D., Demartines, N. \u0026amp; Clavien, P.-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240, 205\u0026ndash;13 (2004).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eItani, K. M. F. \u003cem\u003eet al.\u003c/em\u003e Comparison of laparoscopic and open repair with mesh for the treatment of ventral incisional hernia: a randomized trial. Arch Surg 145, 322\u0026ndash;8; discussion 328 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRogmark, P. \u003cem\u003eet al.\u003c/em\u003e Short-term outcomes for open and laparoscopic midline incisional hernia repair: a randomized multicenter controlled trial: the ProLOVE (prospective randomized trial on open versus laparoscopic operation of ventral eventrations) trial. Ann Surg 258, 37\u0026ndash;45 (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWeiner-Lastinger, L. M. \u003cem\u003eet al.\u003c/em\u003e Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015\u0026ndash;2017. Infect Control Hosp Epidemiol 41, 1\u0026ndash;18 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuijendijk, R. W. \u003cem\u003eet al.\u003c/em\u003e A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med 343, 392\u0026ndash;8 (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDunne, J. R., Malone, D. L., Tracy, J. K. \u0026amp; Napolitano, L. M. Abdominal wall hernias: risk factors for infection and resource utilization. J Surg Res 111, 78\u0026ndash;84 (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFinan, K. R., Vick, C. C., Kiefe, C. I., Neumayer, L. \u0026amp; Hawn, M. T. Predictors of wound infection in ventral hernia repair. Am J Surg 190, 676\u0026ndash;81 (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWhite, T. J., Santos, M. C. \u0026amp; Thompson, J. S. Factors affecting wound complications in repair of ventral hernias. Am Surg 64, 276\u0026ndash;80 (1998).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGrant, A. M. \u0026amp; EU Hernia Trialists Collaboration. Open mesh versus non-mesh repair of groin hernia: meta-analysis of randomised trials based on individual patient data [corrected]. Hernia 6, 130\u0026ndash;6 (2002).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIqbal, C. W. \u003cem\u003eet al.\u003c/em\u003e Long-term outcome of 254 complex incisional hernia repairs using the modified Rives-Stoppa technique. World J Surg 31, 2398\u0026ndash;404 (2007).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCherla, D. V \u003cem\u003eet al.\u003c/em\u003e Decreasing Surgical Site Infections after Ventral Hernia Repair: A Quality-Improvement Initiative. Surg Infect (Larchmt) 18, 780\u0026ndash;786 (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAllegranzi, B. \u003cem\u003eet al.\u003c/em\u003e New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis 16, e276\u0026ndash;e287 (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTong, Q.-J. \u003cem\u003eet al.\u003c/em\u003e A systematic review and meta-analysis on the use of prophylactic topical antibiotics for the prevention of uncomplicated wound infections. Infect Drug Resist 11, 417\u0026ndash;425 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuiras, P., Logan, J. K., Papadopoulos, S. \u0026amp; Whitney, D. Local antimicrobial administration for prophylaxis of surgical site infections. Pharmacotherapy 32, 1006\u0026ndash;19 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcHugh, S. M., Collins, C. J., Corrigan, M. A., Hill, A. D. K. \u0026amp; Humphreys, H. The role of topical antibiotics used as prophylaxis in surgical site infection prevention. J Antimicrob Chemother 66, 693\u0026ndash;701 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSadava, E. E., Krpata, D. M., Gao, Y., Novitsky, Y. W. \u0026amp; Rosen, M. J. Does presoaking synthetic mesh in antibiotic solution reduce mesh infections? An experimental study. J Gastrointest Surg 17, 562\u0026ndash;8 (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAl-Shehri, M. Y. \u003cem\u003eet al.\u003c/em\u003e Topical ampicillin for prophylaxis against wound infection in acute appendicitis. Ann Saudi Med 14, 233\u0026ndash;6 (1994).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFriberg, O. \u003cem\u003eet al.\u003c/em\u003e Antibiotic concentrations in serum and wound fluid after local gentamicin or intravenous dicloxacillin prophylaxis in cardiac surgery. Scand J Infect Dis 35, 251\u0026ndash;4 (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBinneb\u0026ouml;sel, M. \u003cem\u003eet al.\u003c/em\u003e Impact of gentamicin-supplemented polyvinylidenfluoride mesh materials on MMP-2 expression and tissue integration in a transgenic mice model. Langenbecks Arch Surg 395, 413\u0026ndash;20 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSu\u0026aacute;rez-Grau, J. M. \u003cem\u003eet al.\u003c/em\u003e Antibiotic embedded absorbable prosthesis for prevention of surgical mesh infection: experimental study in rats. Hernia 19, 187\u0026ndash;94 (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDeysine, M. Infection control in a hernia clinic: 24 year results of aseptic and antiseptic measure implementation in 4,620 \u0026lsquo;clean cases\u0026rsquo;. Hernia 10, 25\u0026ndash;9 (2006).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchimmer, C. \u003cem\u003eet al.\u003c/em\u003e Gentamicin-collagen sponge reduces sternal wound complications after heart surgery: a controlled, prospectively randomized, double-blind study. J Thorac Cardiovasc Surg 143, 194\u0026ndash;200 (2012).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuzm\u0026aacute;n Valdivia Gomez, G., Guerrero, T. S., Lluck, M. C. \u0026amp; Delgado, F. J. Effectiveness of collagen-gentamicin implant for treatment of \u0026lsquo;dirty\u0026rsquo; abdominal wounds. World J Surg 23, 123\u0026ndash;6; discussion 126-7 (1999).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBennett-Guerrero, E. \u003cem\u003eet al.\u003c/em\u003e Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA 304, 755\u0026ndash;62 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEmile, S. H., Elfallal, A. H., Abdel-Razik, M. A., El-Said, M. \u0026amp; Elshobaky, A. A randomized controlled trial on irrigation of open appendectomy wound with gentamicin- saline solution versus saline solution for prevention of surgical site infection. Int J Surg 81, 140\u0026ndash;146 (2020).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBennett-Guerrero, E. \u003cem\u003eet al.\u003c/em\u003e Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med 363, 1038\u0026ndash;49 (2010).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTubre, D. J., Schroeder, A. D., Estes, J., Eisenga, J. \u0026amp; Fitzgibbons, R. J. Surgical site infection: the \u0026lsquo;Achilles Heel\u0026rsquo; of all types of abdominal wall hernia reconstruction. Hernia 22, 1003\u0026ndash;1013 (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePage, C. P. \u003cem\u003eet al.\u003c/em\u003e Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch Surg 128, 79\u0026ndash;88 (1993).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShlaes, D. M. \u003cem\u003eet al.\u003c/em\u003e Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25, 584\u0026ndash;99 (1997).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoore, R. D., Lietman, P. S. \u0026amp; Smith, C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155, 93\u0026ndash;9 (1987).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBruce, J., Russell, E. M., Mollison, J. \u0026amp; Krukowski, Z. H. The quality of measurement of surgical wound infection as the basis for monitoring: a systematic review. J Hosp Infect 49, 99\u0026ndash;108 (2001).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGignoux, B. \u003cem\u003eet al.\u003c/em\u003e Incidence and risk factors for incisional hernia and recurrence: Retrospective analysis of the French national database. Colorectal Dis 23, 1515\u0026ndash;1523 (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRuiz-Tovar, J. \u003cem\u003eet al.\u003c/em\u003e Effect of gentamicin lavage of the axillary surgical bed after lymph node dissection on drainage discharge volume. Breast 22, 874\u0026ndash;8 (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBinneb\u0026ouml;sel, M. \u003cem\u003eet al.\u003c/em\u003e Intraperitoneally applied gentamicin increases collagen content and mechanical stability of colon anastomosis in rats. Int J Colorectal Dis 24, 433\u0026ndash;40 (2009).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVaneerdeweg, W., Hendriks, J. M., Lauwers, P. R., Ieven, M. \u0026amp; Eyskens, E. J. Effect of gentamicin-containing sponges on the healing of colonic anastomoses in a rat model of peritonitis. Eur J Surg 166, 959\u0026ndash;62 (2000).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGette, M. T., Marks, J. G. \u0026amp; Maloney, M. E. Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol 128, 365\u0026ndash;7 (1992).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDamm, S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health Syst Pharm 68, 323\u0026ndash;7 (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGehrig, K. A. \u0026amp; Warshaw, E. M. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 58, 1\u0026ndash;21 (2008).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKokotovic, D., Bisgaard, T. \u0026amp; Helgstrand, F. Long-term Recurrence and Complications Associated With Elective Incisional Hernia Repair. JAMA 316, 1575\u0026ndash;1582 (2016).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"surgical site infection, topical antibiotics, gentamicin, prevention, incisional hernia repair","lastPublishedDoi":"10.21203/rs.3.rs-4703140/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4703140/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eSurgical site infection (SSI) continues to be a common complication of surgery. The real benefit of using topical antibiotics for the prevention of SSI in abdominal hernia repair surgery is still unknown. This study aimed to evaluate the usefulness of topical gentamicin in SSI prophylaxis in incisional hernia repair with mesh. A randomized controlled trial was conducted in patients undergoing open incisional hernia repair. Patients were randomly assigned to one of two groups: in the gentamicin group, each layer of the abdominal wall was irrigated with gentamicin solution before wound closure, and in the saline solution group (placebo), each layer of the abdominal wall was irrigated with normal saline solution. The incidence of SSI and other surgical site complications was compared between both groups, and the presence of adverse effects with the use of topical gentamicin. Data from 146 patients were included for analysis: 74 in the gentamicin group and 72 in the saline solution group. SSI was observed in six patients (8.1%) in the gentamicin group and eight patients (11.1%) in the saline solution group, with no significant differences (p\u0026thinsp;=\u0026thinsp;0.538) between both groups. No statistically significant differences were observed in the presentation of seroma, hematoma, and surgical wound dehiscence between both groups. No adverse effects were reported from topical application of gentamicin. In this clinical trial, the use of topical gentamicin in incisional hernia repair with mesh did not significantly reduce the incidence of SSI. EU Clinical Trials Register: EudraCT 2018-001860-45 (04/07/2019).\u003c/p\u003e","manuscriptTitle":"Effect of topical gentamicin in preventing surgical site infection in elective incisional hernia repair: a randomized controlled trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-02 13:18:10","doi":"10.21203/rs.3.rs-4703140/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-10-25T13:39:53+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-10-25T11:23:08+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"208990640385836185183906392504466058342","date":"2024-10-14T17:03:34+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-08-27T16:10:29+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"19356347352204373565648219665793998416","date":"2024-08-04T17:23:59+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-07-30T08:45:53+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-07-30T08:42:44+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2024-07-29T17:29:18+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-07-27T12:09:56+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2024-07-08T06:35:56+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ad8897eb-9459-47e4-bab4-68b7b17fbbdf","owner":[],"postedDate":"September 2nd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":36260981,"name":"Health sciences/Diseases"},{"id":36260982,"name":"Health sciences/Medical research"}],"tags":[],"updatedAt":"2024-11-25T16:02:30+00:00","versionOfRecord":{"articleIdentity":"rs-4703140","link":"https://doi.org/10.1038/s41598-024-80112-y","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2024-11-20 15:57:43","publishedOnDateReadable":"November 20th, 2024"},"versionCreatedAt":"2024-09-02 13:18:10","video":"","vorDoi":"10.1038/s41598-024-80112-y","vorDoiUrl":"https://doi.org/10.1038/s41598-024-80112-y","workflowStages":[]},"version":"v1","identity":"rs-4703140","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4703140","identity":"rs-4703140","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}